MAPLE GROVE, Minn. — Upsher-Smith Laboratories on Tuesday announced an exclusive agreement with Pharmathen to develop and distribute a generic product in a market category that had more than $500 million in sales for the 12 months ended July 2016, according to IMS Health data.
Under the agreement, Pharmathen will develop, manufacture and supply the product, and Upsher-Smith will submit the product for Food and Drug Administration approval and handle marketing and distributing in the United States as an Upsher-Smith generic.